STAT+: How AI may create new battles over drug patents
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
You\u2019re reading the web edition of STAT\u2019s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine.\u00a0Sign up to get it<\/a>\u00a0delivered in your inbox every Wednesday.<\/em>\u00a0<\/p>\n<\/p>\n While planning a road trip earlier this year, I discovered that there is a museum that houses old patent models<\/a> in Wilmington, Del. The U.S. patent office used to require physical models of new inventions until it got too unwieldy to store all of them. In 1880, the patent office switched to requiring diagrams instead.<\/p>\n AI is now changing the intellectual property landscape even further. From questions about whether AI can be an inventor and hold a patent to what \u201ca person skilled in the art\u201d might reasonably know, there are a lot of still-to-be-determined issues that Foley Hoag biotech patent lawyer DeAnn Smith is looking forward to seeing worked out in future litigation.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\nHow AI may affect biotech patents<\/h2>\n